Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost? Yolande Lievens, PhD, Caroline Obyn, MSc, Anne-Sophie Mertens, MSc, Dries.

Slides:

Advertisements

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Advertisements

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review David.

Su K. Metcalfe, MD, MPH, Michael T

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

ALK FISH and IHC: You Cannot Have One without the Other

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?

Tumor Regression and Positional Changes in Non-small Cell Lung Cancer During Radical Radiotherapy Gerald Lim, MD, Andrea Bezjak, MD, CM, MSc, Jane Higgins,

Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Intensity-Modulated Radiotherapy for Lung Cancer: Current Status and Future Developments Clara Chan, MD, Stephanie Lang, MSc, Carl Rowbottom, PhD, Matthias.

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

Frank Detterbeck, MD Journal of Thoracic Oncology

Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer Max Dahele, MBChB, MSc, David Palma, MD, Frank Lagerwaard, MD, PhD, Ben Slotman,

Pulmonary Metastasectomy: A Survey of Current Practice Amongst Members of the European Society of Thoracic Surgeons Eveline Internullo, MD, Stephen D.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost? Yolande Lievens, PhD, Caroline Obyn, MSc, Anne-Sophie Mertens, MSc, Dries.

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen,

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy Robert Thompson, MD, Meredith Giuliani, MBBS, Mei Ling Yap,

Mitotic Inhibitors Journal of Thoracic Oncology

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Is Radiotherapy Useful for Treating Pain in Mesothelioma

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Phase I Study of Lenalidomide in Solid Tumors

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

In This Issue Journal of Thoracic Oncology

Survival after Trimodality Treatment for Superior Sulcus and Central T4 Non-small Cell Lung Cancer Paul De Leyn, MD, PhD, Johan Vansteenkiste, MD, PhD,

International Thymic Malignancies Interest Group: A Way Forward

Baseline Characteristics and Mortality Outcomes of Control Group Participants and Eligible Non-Responders in the NELSON Lung Cancer Screening Study Uraujh.

European Lung Cancer Conference (ELCC) 2016 Organisation

S-1 Treatment for Chemorefractory Thymic Carcinoma

IASLC 6th Latin American Conference on Lung Cancer

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Journal of Thoracic Oncology

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

David Garfield, MD Journal of Thoracic Oncology

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Stereotactic Body Radiotherapy for Central Lung Tumors

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

The IASLC Lung Cancer Staging Project

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Presentation transcript:

Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost? Yolande Lievens, PhD, Caroline Obyn, MSc, Anne-Sophie Mertens, MSc, Dries Van Halewyck, MSc, Frank Hulstaert, MD Journal of Thoracic Oncology Volume 10, Issue 3, Pages 454-461 (March 2015) DOI: 10.1097/JTO.0000000000000421 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Cost allocation model. The topmost part of the figure shows the different costs: personnel, equipment, overhead, and direct and indirect material. The lower part shows how these costs were allocated to the different treatments. Indirect costs: costs that cannot be directly assigned to a single treatment, i.e., personnel, equipment, overhead, and indirect material. Personnel and equipment costs: TDABC two-step methodology. Overhead costs: defined at treatment or departmental level (allocated by fraction and by patient). Indirect material costs: allocated by fraction. Direct costs: costs directly assigned to a specific treatment, i.e., direct material costs (masks, fiducials). TDABC, time-driven activity-based costing. Journal of Thoracic Oncology 2015 10, 454-461DOI: (10.1097/JTO.0000000000000421) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Average lung cancer radiotherapy cost. A, Breakdown per resource cost item and for both overhead scenarios. B, Global averages (bars) versus averages per individual centre (dots). Journal of Thoracic Oncology 2015 10, 454-461DOI: (10.1097/JTO.0000000000000421) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Determinants of time and resource use (averages and range at centre level). A, Cost. B, Fractions. C, Time * personnel use during preparation. D, Time * personnel use during treatment delivery. Journal of Thoracic Oncology 2015 10, 454-461DOI: (10.1097/JTO.0000000000000421) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Cost of SBRT for lung cancer by centre, technique and fractionation. If the reported fractionation overlapped with two categories, the same cost was reported for both. SBRT, stereotactic body radiotherapy. Journal of Thoracic Oncology 2015 10, 454-461DOI: (10.1097/JTO.0000000000000421) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions